Henan Newland Pharmaceutical Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 29.76%

Henan Newland Pharmaceutical Co. Ltd. A (301277) has an Asset Resilience Ratio of 29.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Henan Newland Pharmaceutical Co. Ltd. A's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥542.35 Million

≈ $79.36 Million USD Cash + Short-term Investments

Total Assets

CN¥1.82 Billion

≈ $266.71 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how Henan Newland Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Henan Newland Pharmaceutical Co. Ltd. A balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Henan Newland Pharmaceutical Co. Ltd. A carry for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥542.35 Million	29.76%
Total Liquid Assets	CN¥542.35 Million	29.76%

Asset Resilience Insights

Very High Liquidity: Henan Newland Pharmaceutical Co. Ltd. A maintains exceptional liquid asset reserves at 29.76% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Henan Newland Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Henan Newland Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Henan Newland Pharmaceutical Co. Ltd. A (2021–2025)

The table below shows the annual Asset Resilience Ratio data for Henan Newland Pharmaceutical Co. Ltd. A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	30.88%	CN¥549.55 Million ≈ $80.42 Million	CN¥1.78 Billion ≈ $260.40 Million	+1.93pp
2024-12-31	28.95%	CN¥525.16 Million ≈ $76.85 Million	CN¥1.81 Billion ≈ $265.41 Million	-7.67pp
2023-12-31	36.63%	CN¥589.50 Million ≈ $86.26 Million	CN¥1.61 Billion ≈ $235.52 Million	-9.10pp
2022-12-31	45.73%	CN¥701.36 Million ≈ $102.63 Million	CN¥1.53 Billion ≈ $224.44 Million	+44.43pp
2021-12-31	1.30%	CN¥8.67 Million ≈ $1.27 Million	CN¥667.90 Million ≈ $97.74 Million	--

pp = percentage points

About Henan Newland Pharmaceutical Co. Ltd. A

SHE:301277 China Drug Manufacturers - Specialty & Generic

Market Cap

$565.70 Million

CN¥3.87 Billion CNY

Market Cap Rank

#11719 Global

#3350 in China

Share Price

CN¥9.86

Change (1 day)

+0.72%

52-Week Range

CN¥8.70 - CN¥13.63

All Time High

CN¥19.48